Initial evidence has come from studies in patients with type 2 diabetes, where agents like liraglutide and semaglutide have not only improved glycemic control but also been associated with reductions in depressive symptoms [63,64,69]
This changes the terminal value assumption in biologic IP DCF models materially
Los investigadores observaron mejoras potenciales en la regulacin del aumento de peso y los marcadores metablicos en comparacin con los grupos de control
"Design, Synthesis and Biological Evaluation of Neogliptin, a Novel 2-Azabicyclo[2.2.1]heptane-Based Inhibitor of Dipeptidyl Peptidase-4 (DPP-4)"
Parallel efforts are exploring new indications, including neurodegenerative and substance use disorders, metabolic liver disease, arthritis, type 1 diabetes and inflammatory bowel disease